Read More
Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor
Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor"
Post a Comment